RE: RE: RE: TOS investor relations where are they My thoughts? Thanks for asking. I worked as Director of technical services in a Quebec Hospital and one of my projects was rebuilding the sterilisation department. When I read about TOS in the Soleil over 10 years ago I recognised immediately what the implications were and made my first purchase. I was never impressed with the CA. It looked like a group of Quebec City golfing buddies and lacked real industry depth. I believe Régis Labeaume, the present mayor of QC, was once on the CA. I was listening when Germain Carrière, then the CEO, bungled the MD&A during the 4Q 2006/ Q1 2007 report and teleconference. That was when he ineptly explained the difficuties that flexible scopes presented and why sales were not as expected. The shares tanked immediately. All he presented was problems and he had no solutions. At the following AGM he was temporarily replaced by Barry MacDonald. Carrière remained as Chairman and still is, much to my displeasure. In my opinion the CA needs a complete remake starting with the exit of the Chairman. This is another example of a company with a fantastic product that is not being served well by it's CA. Rumble seems to be doing OK but some more transparency is required to convince the market.
My other example of a company destroyed by its CA was/is Railpower, R, they wanted to get their product to market and then fix the bugs. After several fires in their revolutionary railway locomotives ( a Prius on steel wheels) the market dried up. Teachers put $25MM into it and it still went belly up within 12 months. An american company bought the leftovers and is still selling small numbers of locos to small operators
I totally agree that the story needs to be told. It no longer needs to be told to the health sector or to sterilization people. There must be somebody out there that could offer advice on how to market the company. Unfortunately the great unkown, FDA approval, seems to be beyond understanding and is an obvious obstacle and therfore any evolution or developement regarding approval assumes major importance. In my opinion anyone that considers the FDA NSE letter not to be of material information is an idiot and out to ruin TOS. To have people thinking that way running the show is an error.
I have not sold out, but am well under water. I still believe in the product but have learned that averaging down can be dangerous. Averaging up is much more fun. Happened to me with CLM thank the Lord and Richard Quesnel.